Investment Opportunities in Novo Nordisk and Zoetis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 22 2026
0mins
Source: Fool
- Novo Nordisk's Drug Resurgence: Novo Nordisk's Wegovy pill has been approved in the U.S., selling over 170,000 prescriptions in its first month, attracting many new patients despite competitive pressures, indicating strong potential in the weight loss market.
- Sales Warning and Growth Outlook: Although management warns of a potential 13% drop in sales due to pricing competition, Novo Nordisk's revenue has grown by 77% over the past three years, showcasing its long-term growth capability; if Wegovy continues to succeed, both stock price and dividends could rise.
- Zoetis's Market Position: As a leader in animal health, Zoetis has consistently raised its dividend for 12 years, with nearly 10% annualized growth expected over the next 3-5 years, benefiting from global population growth and increased spending on pets by younger generations.
- Stock Price Weakness and Investment Opportunity: Despite recent market volatility due to negative publicity from its canine osteoarthritis drug, Zoetis's current P/E ratio of just over 21 is significantly lower than historical levels, presenting a buying opportunity for investors looking to capitalize on its long-term wealth-building potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 37.450
Low
42.00
Averages
54.67
High
70.00
Current: 37.450
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk Invests €432 Million in Irish Facility Expansion
- Significant Investment: Novo Nordisk has announced a €432 million investment in its Monksland facility in Athlone, Ireland, which will significantly enhance its manufacturing capacity for current and future GLP-1 oral treatments, addressing anticipated market demands.
- Strategic Milestone: This investment reinforces Novo Nordisk's long-term commitment to Ireland, positioning the country as a critical hub for servicing markets outside the US, thereby advancing global healthcare innovation.
- Job Creation: The project is expected to create up to 500 construction jobs, while the existing 260 employees will focus on delivering high-quality oral treatments efficiently and sustainably, enhancing the company's operational capabilities.
- Construction Timeline: The construction has already commenced in 2026 and is expected to be completed gradually from the end of 2027 through 2028, marking a historic investment for Novo Nordisk in Ireland and demonstrating ongoing support for its skilled workforce.
See More
Investors Discuss Potential PayPal Buyout and Stock Picks
- PayPal Buyout Chatter: Amid a down market, PayPal's stock rose on rumors of potential buyouts, highlighting its appeal as a profitable business, although the market remains cautious about its future trajectory.
- Live Oak Bankshares Performance: The bank's stock has surged nearly 20% over the past year, significantly outperforming the market, showcasing its specialization and high-quality loan origination in the small business lending sector, thereby enhancing its competitive edge.
- Upbound's Value Proposition: Upbound attracts investors with a forward P/E ratio of five and a dividend yield exceeding 7%, and despite slower growth, its revenue accelerated to 11% in the past year, indicating stability and potential in the rental market.
- Disruptive Potential of Hims & Hers: The company challenges traditional healthcare with a direct-to-consumer model, facing legal hurdles but is viewed favorably for its long-term growth potential, which could transform the delivery of healthcare services.
See More
Novo Nordisk Stock Plummets 60% Amidst Concerns
- Stock Price Decline: Novo Nordisk's stock has plummeted approximately 60% over the past year, indicating investor concerns about its long-term prospects, particularly in light of competition from Eli Lilly.
- Sales Guidance Downgrade: The company anticipates a decline in adjusted sales of at least 5%, potentially as much as 13%, which is alarming for growth investors and has contributed to the recent sell-off in its stock.
- Legal Action Impact: Novo Nordisk is suing Hims & Hers Health for selling unauthorized versions of its drugs, and if successful in curbing these sales, it could help stabilize its growth rate this year.
- Market Potential Remains: Despite current challenges, Novo Nordisk remains a significant player in the GLP-1 drug market, which is projected to exceed $150 billion by 2035, suggesting that long-term investors may find the current low price-to-earnings ratio appealing.
See More
Novo Nordisk Faces Sales Decline Pressure
- Sales Outlook Decline: Novo Nordisk anticipates adjusted sales to decline by at least 5% and potentially up to 13% this year, indicating severe challenges in a competitive market environment, which has raised investor concerns about its long-term prospects.
- Stock Price Plunge: The stock has lost approximately 60% of its value over the past 12 months, with a current price-to-earnings ratio of just 10, reflecting market pessimism regarding its future growth potential and prompting a sell-off among investors.
- Legal Action Impact: Novo Nordisk has filed a lawsuit against Hims & Hers Health for selling unauthorized versions of its drugs, and if successful, this could help restore sales and improve the company's growth rate, despite the current challenging market conditions.
- Market Opportunities Remain: Despite facing challenges, the GLP-1 drug market is projected to exceed $150 billion by 2035, providing Novo Nordisk with opportunities to maintain a significant presence in this rapidly growing market, especially given the high demand for drug tolerability among users.
See More
Goldman Sachs Downgrades Novo Nordisk to Neutral
- Rating Downgrade: Goldman Sachs has downgraded Novo Nordisk (NVO) from Buy to Neutral due to disappointing Phase 3 results for its next-generation obesity drug, CagriSema, leading to a significant reduction in revenue expectations.
- Price Target Adjustment: The bank has cut its price target for Novo Nordisk from $63 to $41, indicating approximately 9% upside based on the February 27 close, reflecting a cautious market outlook on the company's future performance.
- Sales Forecast Reduction: Analyst James Quigley now projects CagriSema sales in obesity and diabetes to be around $5 billion, down from $11.8 billion previously, resulting in an average 6% cut to topline estimates for 2026-2030.
- Future Uncertainty: Despite the downgrade on CagriSema, Goldman Sachs did not move Novo to Sell, citing potential upside from the launch of the Wegovy pill and possible volume capture acceleration with the unlocking of the Medicare population.
See More
Novo Nordisk Invests €432 Million to Expand Wegovy Production
- Investment Expansion: Novo Nordisk announced a €432 million ($506 million) investment in Ireland to expand production capacity for the Wegovy pill, aiming to meet future global demand, particularly outside the U.S. market.
- Competitive Pressure: This investment follows Novo losing market share to Eli Lilly, with analysts noting that despite competitive pressures, this move demonstrates the company's commitment to the oral medication market, potentially helping to restore market confidence.
- Supply Assurance: Novo has stated that it has resolved supply issues for Wegovy and has enough product to meet U.S. demand; however, challenges remain in meeting global demand, especially as it seeks to launch in other countries.
- Future Outlook: The construction projects in Ireland are set to be completed gradually between 2027 and 2028, expected to include technological upgrades of existing facilities, further enhancing Novo's competitiveness in the obesity drug market, particularly in its strategic focus on oral medications.
See More
Novo Nordisk Invests €432 Million in Irish Facility Expansion
- Significant Investment: Novo Nordisk has announced a €432 million investment in its Monksland facility in Athlone, Ireland, which will significantly enhance its manufacturing capacity for current and future GLP-1 oral treatments, addressing anticipated market demands.
- Strategic Milestone: This investment reinforces Novo Nordisk's long-term commitment to Ireland, positioning the country as a critical hub for servicing markets outside the US, thereby advancing global healthcare innovation.
- Job Creation: The project is expected to create up to 500 construction jobs, while the existing 260 employees will focus on delivering high-quality oral treatments efficiently and sustainably, enhancing the company's operational capabilities.
- Construction Timeline: The construction has already commenced in 2026 and is expected to be completed gradually from the end of 2027 through 2028, marking a historic investment for Novo Nordisk in Ireland and demonstrating ongoing support for its skilled workforce.
See More
Investors Discuss Potential PayPal Buyout and Stock Picks
- PayPal Buyout Chatter: Amid a down market, PayPal's stock rose on rumors of potential buyouts, highlighting its appeal as a profitable business, although the market remains cautious about its future trajectory.
- Live Oak Bankshares Performance: The bank's stock has surged nearly 20% over the past year, significantly outperforming the market, showcasing its specialization and high-quality loan origination in the small business lending sector, thereby enhancing its competitive edge.
- Upbound's Value Proposition: Upbound attracts investors with a forward P/E ratio of five and a dividend yield exceeding 7%, and despite slower growth, its revenue accelerated to 11% in the past year, indicating stability and potential in the rental market.
- Disruptive Potential of Hims & Hers: The company challenges traditional healthcare with a direct-to-consumer model, facing legal hurdles but is viewed favorably for its long-term growth potential, which could transform the delivery of healthcare services.
See More
Novo Nordisk Stock Plummets 60% Amidst Concerns
- Stock Price Decline: Novo Nordisk's stock has plummeted approximately 60% over the past year, indicating investor concerns about its long-term prospects, particularly in light of competition from Eli Lilly.
- Sales Guidance Downgrade: The company anticipates a decline in adjusted sales of at least 5%, potentially as much as 13%, which is alarming for growth investors and has contributed to the recent sell-off in its stock.
- Legal Action Impact: Novo Nordisk is suing Hims & Hers Health for selling unauthorized versions of its drugs, and if successful in curbing these sales, it could help stabilize its growth rate this year.
- Market Potential Remains: Despite current challenges, Novo Nordisk remains a significant player in the GLP-1 drug market, which is projected to exceed $150 billion by 2035, suggesting that long-term investors may find the current low price-to-earnings ratio appealing.
See More
Novo Nordisk Faces Sales Decline Pressure
- Sales Outlook Decline: Novo Nordisk anticipates adjusted sales to decline by at least 5% and potentially up to 13% this year, indicating severe challenges in a competitive market environment, which has raised investor concerns about its long-term prospects.
- Stock Price Plunge: The stock has lost approximately 60% of its value over the past 12 months, with a current price-to-earnings ratio of just 10, reflecting market pessimism regarding its future growth potential and prompting a sell-off among investors.
- Legal Action Impact: Novo Nordisk has filed a lawsuit against Hims & Hers Health for selling unauthorized versions of its drugs, and if successful, this could help restore sales and improve the company's growth rate, despite the current challenging market conditions.
- Market Opportunities Remain: Despite facing challenges, the GLP-1 drug market is projected to exceed $150 billion by 2035, providing Novo Nordisk with opportunities to maintain a significant presence in this rapidly growing market, especially given the high demand for drug tolerability among users.
See More
Goldman Sachs Downgrades Novo Nordisk to Neutral
- Rating Downgrade: Goldman Sachs has downgraded Novo Nordisk (NVO) from Buy to Neutral due to disappointing Phase 3 results for its next-generation obesity drug, CagriSema, leading to a significant reduction in revenue expectations.
- Price Target Adjustment: The bank has cut its price target for Novo Nordisk from $63 to $41, indicating approximately 9% upside based on the February 27 close, reflecting a cautious market outlook on the company's future performance.
- Sales Forecast Reduction: Analyst James Quigley now projects CagriSema sales in obesity and diabetes to be around $5 billion, down from $11.8 billion previously, resulting in an average 6% cut to topline estimates for 2026-2030.
- Future Uncertainty: Despite the downgrade on CagriSema, Goldman Sachs did not move Novo to Sell, citing potential upside from the launch of the Wegovy pill and possible volume capture acceleration with the unlocking of the Medicare population.
See More
Novo Nordisk Invests €432 Million to Expand Wegovy Production
- Investment Expansion: Novo Nordisk announced a €432 million ($506 million) investment in Ireland to expand production capacity for the Wegovy pill, aiming to meet future global demand, particularly outside the U.S. market.
- Competitive Pressure: This investment follows Novo losing market share to Eli Lilly, with analysts noting that despite competitive pressures, this move demonstrates the company's commitment to the oral medication market, potentially helping to restore market confidence.
- Supply Assurance: Novo has stated that it has resolved supply issues for Wegovy and has enough product to meet U.S. demand; however, challenges remain in meeting global demand, especially as it seeks to launch in other countries.
- Future Outlook: The construction projects in Ireland are set to be completed gradually between 2027 and 2028, expected to include technological upgrades of existing facilities, further enhancing Novo's competitiveness in the obesity drug market, particularly in its strategic focus on oral medications.
See More
